Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design — HOME Study report number 1

2014 ◽  
Vol 37 (2) ◽  
pp. 294-300 ◽  
Author(s):  
Emily Y. Chew ◽  
Traci E. Clemons ◽  
Susan B. Bressler ◽  
Michael J. Elman ◽  
Ronald P. Danis ◽  
...  
Keyword(s):  
Early Detection ◽  
Randomized Trial ◽  
Macular Degeneration ◽  
Study Design ◽  
Home Monitoring ◽  
Age Related Macular Degeneration ◽  
Monitoring Device ◽  
Home Study ◽  
Study Report ◽  
Age Related

scholarly journals Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration

2021 ◽  
Vol 10 (7) ◽  
pp. 1355
Author(s):  
Allen C. Ho ◽  
Jeffrey S. Heier ◽  
Nancy M. Holekamp ◽  
Richard A. Garfinkel ◽  
Byron Ladd ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Early Detection ◽  
Monitoring System ◽  
Real World ◽  
Home Monitoring ◽  
Age Related Macular Degeneration ◽  
Home Study ◽  
The Real ◽  
Home Telemonitoring ◽  
Age Related

The real-world performance of a home telemonitoring strategy (ForeseeHome AMD Monitoring System®, Notal Vision, Inc.,Manassas VA, USA) was evaluated and compared to the device arm of the AREDS2-HOME study among patients with intermediate AMD (iAMD) who converted to neovascular AMD (nAMD). All patients with confirmed conversion to nAMD who used the home monitoring system from 10/2009 through 9/2018 were identified by Notal Vision Diagnostic Clinic’s medical records. Selected outcome variables were evaluated, including visual acuity (VA) at baseline and at conversion, and change in visual acuity (VA) from baseline to time of conversion. In total, 8991 patients performed 3,200,999 tests at a frequency of 5.6 ± 3.2 times/week. The 306 eyes that converted from iAMD to nAMD over the study period (a 2.7% annual rate) were included in the analyses. There was a median (interquartile range) change of −3.0 (0.0–(−10.0)) letters among converted eyes, 81% [95% confidence interval (72–88%)] maintained a VA ≥ 20/40 at the time of conversion, while 69% of the conversion detections were triggered by system alerts. The real-world performance of an at-home testing strategy was similar to that reported for the device arm of the AREDS2-HOME study. The home telemonitoring system can markedly increase early detection of conversion to nAMD.

scholarly journals Qualifying to Use a Home Monitoring Device for Detection of Neovascular Age-Related Macular Degeneration

2015 ◽  
Vol 133 (12) ◽  
pp. 1425 ◽  
Author(s):  
Merina Thomas ◽  
Yulia Wolfson ◽  
Shiri Zayit-Soudry ◽  
Susan B. Bressler ◽  
Neil M. Bressler
Keyword(s):  
Macular Degeneration ◽  
Home Monitoring ◽  
Age Related Macular Degeneration ◽  
Monitoring Device ◽  
Age Related

Patient Use of Dietary Supplements, Home Monitoring, or Genetic Testing for Nonneovascular Age-Related Macular Degeneration

2021 ◽  
pp. 247412642198922
Author(s):  
Brittany C. Tsou ◽  
T.Y. Alvin Liu ◽  
Jun Kong ◽  
Susan B. Bressler ◽  
J. Fernando Arevalo ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Macular Degeneration ◽  
Dietary Supplements ◽  
Home Monitoring ◽  
Cross Sectional Study ◽  
Age Related Macular Degeneration ◽  
Cross Sectional ◽  
Supplement Use ◽  
Age Related ◽  
Disease Study

Purpose: This work evaluated the use and type of dietary supplements and home monitoring for nonneovascular age-related macular degeneration (AMD), as well as the prevalence of genetic testing among patients with AMD. Methods: A cross-sectional study was conducted of 129 participants older than 50 years who completed self-administered questionnaires regarding usage and type of dietary supplements and home monitoring, as well as the participants’ use of genetic testing for AMD. Results: Of 91 participants with AMD, 83 (91.2%) took vitamins, including 55 (60.4%) who used an Age-Related Eye Disease Study (AREDS) or AREDS2 formulation. Of 38 without AMD, 31 (81.6%) took vitamins (difference from participants with AMD = 9.6% [95% CI, 0%-23.2%]), including 2 on an AREDS formulation. Among 82 participants with AMD who were AREDS candidates (intermediate or advanced AMD in 1 or both eyes), 51 (62.2%; 95% CI, 51.7%-72.7%) took an AREDS or AREDS2 formulation, and 31 (37.8%) did not (5 were unsure). Additionally, 50 (61.0%; 95% CI, 50.4%-71.6%) AREDS candidates did some type of home monitoring. Only 1 (1.2%; 95% CI, 0%-3.6%) underwent genetic testing for AMD. Among 9 with AMD who were not AREDS candidates, 4 (44.4%) used an AREDS formulation, 4 (44.4%) did not, and 1 (11.1%) was unsure; only 1 (11.1%) of these 9 performed home monitoring. Conclusions: Despite similar results from past surveys and AREDS2 data supporting supplement use in 2013 and home monitoring in 2014, these findings suggest about one-third of AREDS candidates do not do so, providing further support for improving education regarding appropriate supplement and home monitoring usage. Genetic testing for AMD also appears infrequent.

Sign in / Sign up

Export Citation Format

Share Document